Enhancing Human Treg Cell Induction through Engineered Dendritic Cells and Zinc Supplementation

Area of Science:

• Immunology
• Endocrinology
• Cell Biology

Background:

• Regulatory T (Treg) cells are crucial for managing immune-mediated diseases.
• Restoring Treg function in patients is a significant therapeutic challenge.
• Dendritic cells (DCs) synthesize 1,25-dihydroxy vitamin D (1,25(OH)2D), which can induce Treg cells, but high concentrations cause side effects like hypercalcemia.

Purpose of the Study:

• To investigate the efficacy of 1α-hydroxylase-overexpressing DCs in inducing human CD4+FOXP3+Treg cells.
• To determine the optimal concentration range of 1,25(OH)2D for Treg induction.
• To explore the role of zinc in augmenting the Treg-inducing capacity of engineered DCs.

Main Methods:

• Overexpression of 1α-hydroxylase in DCs to de novo synthesize 1,25(OH)2D.
• In vivo assessment of 1,25(OH)2D synthesis by engineered DCs.
• Evaluation of Treg cell induction by engineered DCs with and without zinc supplementation.
• Comparison of engineered DCs with parental DCs at physiological 25-hydroxyvitamin D levels.

Main Results:

• Effective Treg induction by 1,25(OH)2D occurs within a specific concentration range.
• 1α-hydroxylase-overexpressing DCs synthesize 1,25(OH)2D within this effective range, inducing Treg cells without hypercalcemia.
• 1α-hydroxylase expression levels are critical for DC-mediated Treg induction.
• Zinc supplementation significantly enhances the Treg-inducing capacity of engineered DCs.

Conclusions:

• 1α-hydroxylase-overexpressing DCs represent a promising strategy for Treg cell therapy in immune-mediated diseases.
• The combination of engineered DCs and zinc offers a novel therapeutic approach.
• This strategy overcomes the limitations of high-dose vitamin D therapy, avoiding hypercalcemia.